☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
FLT3 Mutation
Astellas' Xospata (gilteritinib) Receives NMPA's Conditional Approval for R/R AML with a FLT3 Mutation
February 4, 2021
Astellas Reports NMPA's Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults
April 10, 2020
Astellas' Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mut...
January 15, 2020
Astellas' Xospata (gilteritinib) Receives EC's Approval as Monotherapy for Relapsed or Refractory Acute Myeloid Leukemia with a FL...
October 25, 2019
Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation- in the US
December 12, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.